Five deaths, reported to the manufacturer, occurred during the administration of Raplon. Other drugs on the market may be prescribed for the same purpose, and this withdrawal does not affect the overall availability of anesthesiology drugs. Although the drug's approved labeling did note the occurrence of bronchospasm in a small percentage of clinical trial patients receiving the drug, post-marketing reports indicate that the risk of injury from bronchospasm may be greater than was suggested in clinical trials.
More information is available in the company's market withdrawal letter .
SafetyAlerts compiles comprehensive safety recall information for the United States. SafetyAlerts Newsletter is a free email service to warn consumers of faulty products and contaminated foods. LLC Copyright 1998 - 2001. All Rights Reserved.